Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Minseok Albert | - |
dc.contributor.author | Kim, Seung Up | - |
dc.contributor.author | Sinn, Dong Hyun | - |
dc.contributor.author | Jang, Jeong Won | - |
dc.contributor.author | Lim, Young-Suk | - |
dc.contributor.author | Ahn, Sang Hoon | - |
dc.contributor.author | Shim, Jae-Jun | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Baek, Yang Hyun | - |
dc.contributor.author | Kim, Sang Gyune | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Choe, Won Hyeok | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Lee, Hyun Woong | - |
dc.contributor.author | Kwon, Jung Hyun | - |
dc.contributor.author | Lee, Sung Won | - |
dc.contributor.author | Jang, Jae Young | - |
dc.contributor.author | Kim, Hwi Young | - |
dc.contributor.author | Park, Yewan | - |
dc.contributor.author | Kim, Gi-Ae | - |
dc.contributor.author | Yang, Hyun | - |
dc.contributor.author | Lee, Han Ah | - |
dc.contributor.author | Koh, Myeongseok | - |
dc.contributor.author | Lee, Young-Sun | - |
dc.contributor.author | Kim, Minkoo | - |
dc.contributor.author | Chang, Young | - |
dc.contributor.author | Kim, Yoon Jun | - |
dc.contributor.author | Yoon, Jung-Hwan | - |
dc.contributor.author | Zoulim, Fabien | - |
dc.contributor.author | Lee, Jeong-Hoon | - |
dc.date.available | 2021-02-15T01:14:20Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 0017-5749 | - |
dc.identifier.issn | 1468-3288 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/49204 | - |
dc.description.abstract | Objective Direct comparison of the clinical outcomes between nucleos(t)ide analogue (NA) discontinuation versus NA continuation has not been performed in patients with chronic hepatitis B who achieved HBsAg-seroclearance. Whether NA discontinuation was as safe as NA continuation after NA-induced surface antigen of HBV (HBsAg) seroclearance was investigated in the present study. Designs This multicentre study included 276 patients from 16 hospitals in Korea who achieved NA-induced HBsAg seroclearance: 131 (47.5%) discontinued NA treatment within 6 months after HBsAg seroclearance (NA discontinuation group) and 145 (52.5%) continued NA treatment (NA continuation group). Primary endpoint was HBsAg reversion and secondary endpoints included serum HBV DNA redetection and development of hepatocellular carcinoma (HCC). Results During follow-up (median=26.9 months, IQR=12.2-49.2 months), 10 patients (3.6%) experienced HBsAg reversion, 6 (2.2%) showed HBV DNA redetection and 8 (2.9%) developed HCC. Compared with NA continuation, NA discontinuation was not associated with HBsAg reversion in both univariable (HR=0.45, 95% CI=0.12 to 1.76, log-rank p=0.24) and multivariable analyses (adjusted HR=0.65, 95% CI=0.16 to 2.59, p=0.54). The cumulative probabilities of HBsAg reversion at 1, 3 and 5 years were 0.8%, 2.3% and 5.0% in the NA discontinuation group, and 1.5%, 6.3% and 8.4% in the NA continuation group, respectively. NA discontinuation was not associated with higher risk of either HBV redetection (HR=0.83, 95% CI=0.16 to 4.16, log-rank p=0.82) or HCC development (HR=0.53, 95% CI=0.12 to 2.23, log-rank p=0.38). Conclusion The discontinuation of NA was not associated with a higher risk of either HBsAg reversion, serum HBV DNA redetection or HCC development compared with NA continuation among patients who achieved HBsAg seroclearance with NA. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BMJ Publishing Group | - |
dc.title | Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1136/gutjnl-2019-320015 | - |
dc.identifier.scopusid | 2-s2.0-85082521120 | - |
dc.identifier.wosid | 000591525700017 | - |
dc.identifier.bibliographicCitation | Gut, v.69, no.12, pp 2214 - 2222 | - |
dc.citation.title | Gut | - |
dc.citation.volume | 69 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2214 | - |
dc.citation.endPage | 2222 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | CHRONIC HEPATITIS-B | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | ENTECAVIR THERAPY | - |
dc.subject.keywordPlus | SURFACE-ANTIGEN | - |
dc.subject.keywordPlus | REDUCED RISK | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | REDUCTION | - |
dc.subject.keywordAuthor | antivirals | - |
dc.subject.keywordAuthor | HBsAg | - |
dc.subject.keywordAuthor | HBV DNA redetection | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.